What is the effect of patients taking Jisandai (Bingtonsha) to treat hepatitis C?

Epclusa (Epclusa), composed of Sofosbuvir (Sofosbuvir) and Velpatasvir (Velpatasvir), is a drug used to treat hepatitis C (HCV). Jisandai (Bingtonsha) is a broad-spectrum antiviral drug for the treatment of hepatitis C, covering all major hepatitis C virus genotypes. Its efficacy and safety have been verified in multiple clinical trials, showing excellent therapeutic effects.

1. Clinical trial data

1.1 Efficacy Research: The efficacy of Jisandai (Bingtonsha) has been widely verified in multiple clinical trials. A key clinical trial is the ASTRAL-1 study, which evaluates Jisanda (bingtonsa) for the treatment of hepatitis C 1 infection. Results from the study showed that **96%**of patients who received 12weeks of Bintonsa® achieved a sustained virological response (SVR), meaning that the virus was undetectable 6 months after the end of treatment. This shows thatJisandai (Bingtonsha) has a very significant therapeutic effect on1 type hepatitis C.

In the ASTRAL-2 and ASTRAL-3 studies, Jisandai (bingtonsa) also showed high efficacy in the treatment of hepatitis C 2 types and 3 types. In these studies, **94% to 98%** achieved SVR among patients who received 12 weeks of treatment. These data show that Jisandai (Bingtonsha) has a good effect on different genotypes of hepatitis C virus.

1.2 Patients with liver cirrhosis: For patients with liver cirrhosis, the effect of Jisanda (Bingtonsha) is also significant. In the ASTRAL-4 study, the efficacy of Bitongsa) was evaluated in patients with moderate to severe cirrhosis. The results showed that after 12 weeks Among the patients treated with Jisanda (Bingtonsa) , **93%** achieved SVR. These results show that the efficacy of Jisanda (Bingtonsa) is also high in patients with cirrhosis, indicating that the drug can effectively treat hepatitis C combined with cirrhosis.

2. Safety and Tolerability

The safety and tolerability of Jisandai (Bingtonsa) have also been positively evaluated in clinical trials. Most patients experience mild side effects during treatment with GISANDA (Bingtonsa), mainly including headache, fatigue, nausea, etc. These side effects are usually transient and well tolerated by most patients.

In the ASTRAL series of studies, Gsanda (Bingtonsa) had a lower incidence of side effects, and the incidence of serious side effects was also rare. Generally speaking, the safety profile of Gsanda (Bingtonsa) is good and has a lower incidence of side effects compared with other drugs for the treatment of hepatitis C.

3. Durability of treatment

An important advantage of Jisandai (Bingtonsha) is the durability of its long-term efficacy. Sustained virological response (SVR) is an important indicator of the success of hepatitis C treatment. The data show that patients treated with Gisanda (Bingtonsa) had a very high SVR rate 6 months after the end of treatment, indicating that most patients are able to maintain viral clearance for a long time after the end of treatment. This long-lasting efficacy has important implications for reducing viral recurrence and improving patients' long-term health.

4. Effects on special groups

Bingtonsa has shown consistent efficacy in different patient populations, including HIV-coinfected hepatitis C patients, patients with impaired renal function, and pregnant women (although Bingtonsa should be used with caution in pregnant women). In these special populations, Gsanda (Bingtonsa) still shows good efficacy and safety, although additional monitoring and treatment adjustments may be needed for some special populations.

Overall,Jisandai (Bingtonsa) has shown excellent results in the treatment of hepatitis C. According to data from multiple clinical trials, Jisandai (Bingtonsa) is effective against major hepatitis C virus genotypes (including 1 type, 2 type, 3types and 4 types) are highly efficacious, with treatment success rates (SVR) significantly higher than many other treatment options. Jisandai (Bingtonsa) is also relatively safe, with side effects usually mild and well tolerated by most patients.

The long-term efficacy and good safety profile of Jisandai (Bingtonsha) make it an important choice for the treatment of hepatitis C. For patients with hepatitis C of different genotypes, especially those with cirrhosis or other comorbidities, GISANDA (bingtonsa) provides an effective and well-tolerated treatment option. When patients receive treatment with Gesanda (Bingtonsa), they still need to conduct regular follow-up and monitoring according to the doctor's recommendations to ensure the best effect and safety of the treatment.